Advances in Understanding the Molecular Mechanisms of the Cardiovascular Toxicity of Targeted Cancer Therapies

doi:10.3969/j.issn.1007-9572.2018.00.246

Abstract

Abstract: Molecular targeted therapy is a revolutionary approach in cancer treatment that improves the quality of life of patients and prolongs patient life.However，targeted drugs often have cardiovascular toxicity.In this article，we review the adverse cardiovascular events associated with targeted therapies，including cardiac dysfunction and heart failure，arrhythmias，pulmonary hypertension，hypertension，arterial and venous ischemia and hemorrhage.We also summarize the mechanisms that contribute to the cardiovascular side effects of target drugs.

Key words: Neoplasms, Antineoplastic agents, Cardiovascular diseases, Toxic side effects, Review

摘要： 分子靶向治疗是癌症治疗革命性改变，其提高了患者生活质量，延长了患者寿命，但此类药物多具有心血管毒性。本文总结了与靶向治疗相关的心血管不良事件，包括心功能障碍、心力衰竭、心律失常、肺动脉高压、高血压以及动脉和静脉缺血、出血，总结了造成心血管毒副作用的相关机制，旨在为今后的研究提供帮助。

关键词: 肿瘤, 抗肿瘤药, 心血管疾病, 毒副作用, 综述

QI Hong-tao,PENG Zong-yu. Advances in Understanding the Molecular Mechanisms of the Cardiovascular Toxicity of Targeted Cancer Therapies[J]. Chinese General Practice, 2018, 21(27): 3403-3406. DOI: 10.3969/j.issn.1007-9572.2018.00.246.
齐洪涛,彭宗玉. 癌症靶向治疗后心血管毒副作用的分子机制研究进展[J]. 中国全科医学, 2018, 21(27): 3403-3406. DOI: 10.3969/j.issn.1007-9572.2018.00.246.

References

［1］CHANG H M，MOUDGIL R，SCARABELLI T，et al.Cardiovascular complications of cancer therapy：best practices in diagnosis，prevention，and management：part 1［J］.J Am Coll Cardiol，2017，70（20）：2536-2551.DOI：10.1016/j.jacc.2017.09.1096.3405
［2］ESCALANTE C P，CHANG Y C，LIAO K，et al.Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents［J］.Support Care Cancer，2016，24（9）：4057–4074 .DOI：10.1007/s00520-016-3310-3.3405
［3］CHOUEIRI T K，MAYER E L，JE Y，et al.Congestive heart failure risk in patients with breast cancer treated with bevacizumab［J］.J Clin Oncol，2011，29（6）：632–638.DOI：10.1200/JCO.2010.31.9129.3405
［4］BIANCO C M，Al-KINDI S G，OLIVEIRA G H，et al.Advanced heart failure therapies for cancer therapeutics– related cardiac dysfunction［J］.Heart Fail Clin，2017，13（2）：327-336.DOI：10.1016/j.hfc.2016.12.005.3405
［5］KROP I E，SUTER T M，DANG C T，et al.Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as （neo）adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer［J］.J Clin Oncol，2015，33（10）：1136–1142.DOI：10.1200/JCO.2014.58.7782.3405
［6］SENDUR M A，AKSOY S，ALTUNDAG K.Cardiotoxicity of novel HER2-targeted therapies［J］.Curr Med Res Opin，2013，29（8）：1015-1024.DOI：10.1185/03007995.2013.807232.3405
［7］BLOOM M W，HAMO C E，CARDINALE D，et al.Cancer therapy-related cardiac dysfunction and heart failure：part 1：definitions，pathophysiology，risk factors，and imaging［J］.Circ Heart Fail，2016，9（1）：e002661.DOI：10.1161/CIRCHEARTFAILURE.115.002661.3405
［8］KLOTH J S，PAGANI A，VERBOOM M C，et al.Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors［J］.Br J Cancer，2015，112（6）：1011–1016.DOI：10.1038/bjc.2015.82.3406
［9］TAMARGO J，CABALLERO R，DELPON E.Cancer chemotherapy and cardiac arrhythmias：a review［J］.Drug Saf，2015，38（2）：129-152.DOI：10.1007/s40264-014-0258-4.3406
［10］FRADLEY M G，PINILLA-IBARZ J.Arrhythmic complications of tyrosine kinase inhibitors［J］.Future Cardiol，2015，11（4）：395-399.DOI：10.2217/FCA.15.42.3406
［11］BUZA V，RAJAGOPALAN B，CURTIS A B.Cancer treatment-induced arrhythmias focus on chemotherapy and targeted therapies［J］.Circ Arrhythm Electrophysiol，2017，10（8）：e005443.DOI：10.1161/CIRCEP.117.005443.3406
［12］MARKMAN T M，NAZARAN S.Arrhythmia and electrophysiological effects of chemotherapy：a review［J］.Oncology，2016，91（2）：61-68.DOI：10.1159/000446374.3406
［13］VIGANEGO F，SINGH R，FRADLEY M G.Arrhythmias and other electrophysiology issues in cancer patients receiving chemotherapy or radiation［J］.Curr Cardiol Rep，2016，18（6）：52.DOI：10.1007/s11886-016-0730-0.3406
［14］SHAH N P，WALLIS N，FARBER H W，et al.Clinical features of pulmonary arterial hypertension in patients receiving dasatinib［J］.Am J Hematol，2015，90（11）：1060–1064.DOI：10.1002/ajh.24174.3406
［15］TAJIRI K，AONUMA K，SEKINE I.Cardiovascular toxic effects of targeted cancer therapy［J］.Jpn J Clin Oncol，2017，5（20）：1-7.DOI：10.1093/jjco/hyx071.3406
［16］MCGEE M，WHITEHEAD N，MARTIN J，et al.Drug-associated pulmonary arterial hypertension［J］.Clin Toxicol（Phila），2018，6（5）：1-9.DOI：10.1080/15563650.2018.1447119.3406
［17］GUIGNABERT C，PHAN C，SEFERIAN A，et al.Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertention［J］.J Clin Invest，2016，126（9）：3207-3218.DOI：10.1172/JCI86249.3406
［18］SUNDARARAJAN S，KUMAR A，POONGKUNRAN M，et al.Cardiovascular adverse effects of targeted antiangiogenic drugs：mechanisms and management［J］.Future Oncol，2016，12（8）：1067-1080.DOI：10.2217/fon.16.4.3406
［19］MOSLEHI J J，DEININGER M.Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia［J］.J Clin Oncol，2015，33（35）：4210-4218.DOI：10.1200/JCO.2015.62.4718.3406
［20］ABDEL-QADIR H，ETHIER J L，LEE D S，et al.Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy：a systematic review and meta-analysis［J］.Cancer Treat Rev，2017，53：120-127.DOI：10.1016/j.ctrv.2016.12.002.3406
［21］BOSSAER J B，GERACI S A，CHAKRABORTY K.Cardiovascular toxicity and management of targeted cancer therapy［J］.Am J Med Sci，2016，351（5）：535-543.DOI：10.1016/j.amjms.2016.02.023.3406
［22］HERRMANN J，YANG E H，IIIESCU C A，et al.Vascular toxicities of cancer therapies：the old and new——an evolving avenue［J］.Circulation，2016，133（13）：1272-1289.DOI：10.1161/CIRCULATIONAHA.115.018347.3406
［23］RANPURA V，HAPANI S，CHUANG J，et al.Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients：a meta-analysis of randomized controlled trials［J］.Acta Oncol，2010，49（3）：287–297.DOI：10.3109/02841860903524396.3406
［24］QI W X，SHEN Z，TANG L N，et al.Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors：an up-to-date meta-analysis［J］.Crit Rev Oncol Hematol，2014，92（2）：71–82.DOI：10.1016/j.critrevonc.2014.04.004.3406
［25］HAGUET H，DOUXFILS J，MULLIER F.Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors：a systematic review and meta-analysis［J］.Expert Opin Drug Saf，2017，16（1）：5-12.DOI：10.1080/14740338.2017.1261824.3406
［26］WINNIK S，LOHMANN C，SICILIANI G，et al.Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis—implications for cardiovascular safety［J］.Int J Cardiol，2013，168（3）：2453–2461.DOI：10.1016/j.ijcard.2013.03.010.3406
［27］LOREN C P，ASLAN J E，RIGG R A，et al.The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif（ITAM） signaling，platelet activation and aggregate formation under shear［J］.Thromb Res，2015，135（1）：155–160.DOI：10.1016/j.thromres.2014.11.009.3406
［28］GOPAL S，MILLER K B，JAFFE I Z.Molecular mechanisms for vascular complications of targeted cancer therapies［J］.Clin Sci，2016，130（20）：1763-1779.DOI：10.1042/CS20160246.3406
［29］HAPANI S，SHER A，CHU D，et al.Increased risk of serious hemorrhage with bevacizumab in cancer patients：a meta-analysis［J］.Oncology，2010，79（1/2）：27–38.DOI：10.1159/000314980.3406
［30］HANG X F，XU W S，WANG J X，et al.Risk of high-grade bleeding in patients with cancer treated with bevacizumab：a meta-analysis of randomized controlled trials［J］.Eur J Clin Pharmacol，2011，67（6）：613–623.DOI：10.1007/s00228-010-0988-x.3406
［31］HENNING R J，HARBISON R D.Cardio-oncology：cardiovascular complications of cancer therapy［J］.Future Cardiol，2017，13（4）：379-396.DOI：10.2217/fca-2016-0081.3406
［32］KILICKAP S，ABALI H，CELIK I.Bevacizumab，bleeding，thrombosis，and warfarin［J］.J Clin Oncol，2003，21（18）：3542.DOI：10.1200/JCO.2003.99.046.3406

[1]	XU Baichuan, WANG Yan, ZHANG Peng, LI Yiting, LIU Feilai, XIE Yang. Research and Analysis of Screening Tools for Chronic Obstructive Pulmonary Disease Comorbidity Lung Cancer [J]. Chinese General Practice, 2025, 28(30): 3847-3852.
[2]	ZHOU Sheng, DENG Changsheng, ZOU Guanyang, SONG Jianping. Research Progress on the Pathogenesis of Complications of Malaria in Cardiovascular Diseases [J]. Chinese General Practice, 2025, 28(27): 3466-3472.
[3]	HU Jieman, TAN Feixiang, YUAN Anxin, CHEN Shiyu, TANG Chulei, YIN Yueheng, BA Lei, XU Qin. Analysis of the Trajectory of Postoperative Frailty and Influencing Factors in Patients with Colorectal Cancer [J]. Chinese General Practice, 2025, 28(26): 3276-3282.
[4]	XIANG Xinyue, ZHANG Bingqing, OUYANG Yuqin, TANG Wenjuan, FENG Wenhuan. Impact of Short-term Medical Weight Loss on Atherosclerotic Cardiovascular Disease Risk in Patients with Obesity [J]. Chinese General Practice, 2025, 28(26): 3229-3239.
[5]	LIU Yinyin, SUI Hongping, LI Tingting, JIANG Tongtong, SHI Tieying, XIA Yunlong. Advances in Risk Prediction Models for Cardiotoxicity Associated with Breast Cancer Treatment [J]. Chinese General Practice, 2025, 28(24): 3072-3078.
[6]	PAN Yaojia, FU Fanglin, HAN Zheng, SUN Meng, GU Huaicong, WANG Weiqiang. Correlation of the Type of Obesity with the Cardiometabolic Multimorbidity: a Study in Male and Female Middle-aged Residents in Anhui Province [J]. Chinese General Practice, 2025, 28(18): 2285-2293.
[7]	HAN Zheng, SUN Meng, FU Fanglin, PAN Yaojia, WANG Weiqiang. A Study on the Relationship between the Triglyceride-Glucose Index and Cardiometabolic Multimorbidity in Individuals Aged 50 and Above [J]. Chinese General Practice, 2025, 28(18): 2278-2284.
[8]	ZHANG Bingqing, WANG Zhongkai, WU Changyong, SUN Huang, LI Ruijie, LIU Wenjie, LUO Yihua, ZHENG Lihui, PENG Yunzhu. Changes and Trend Prediction in the Global Burden of Congenital Heart Defects, 1990-2021 [J]. Chinese General Practice, 2025, 28(18): 2253-2261.
[9]	JIANG Xiaoman, XU Xinyi, DING Lingyu, GUO Yinning, MIAO Xueyi, CHEN Li, XU Qin. Clinical Characteristics and Correlation between Preoperative Frailty and Metabolic Syndrome among Older Patients with Gastric Cancer [J]. Chinese General Practice, 2025, 28(17): 2134-2141.
[10]	CAO Qinhan, ZHUO Xiao, XIA Yuhan, CHE Yangxi, CHEN Min. Interpretation of Updated NCCN Clinical Guidelines for Rectal Cancer (2024.V1/V2) [J]. Chinese General Practice, 2025, 28(17): 2070-2074.
[11]	AN Qinyu, WANG Yiying, ZHANG Xiaodan, ZHANG Tianlin, ZHAN Qingqing, ZHANG Fuyan, LIU Tao, WU Yanli. Prospective Cohort Study of the Impact of Socioeconomic Status and Healthy Lifestyle on Cardiovascular Disease [J]. Chinese General Practice, 2025, 28(16): 2017-2024.
[12]	NIE Yuanyuan, FANG Da, XU Hao, YANG Donghui, BI Yan, GU Tianwei. Clinical Characteristics and Cardiovascular Disease Risk of Type 2 Diabetes Populations with Different Liver Fibrosis Risks [J]. Chinese General Practice, 2025, 28(15): 1847-1854.
[13]	MA Guifen, ZHANG Qian, SUN Jing. Interpretation of the Key Updates in the Latest Version of 2024 NCCN Clinical Practice Guidelines for Gastric Cancer [J]. Chinese General Practice, 2025, 28(14): 1681-1688.
[14]	YUAN Xiaorui, TAN Yanlin, FU Chun. Construction of the Predictive Model for Lymph Node Metastasis in Patients with Epithelial Ovarian Cancer: Based on ¹⁸F-FDG PET/CT Radiomics Technology [J]. Chinese General Practice, 2025, 28(12): 1465-1472.
[15]	ZHANG Yushuang, WU Zhongbing, HUANG Ming, JIA Lei, GAO Shuang, ZHAO Weipeng, LI Jing. Study on Metabolic Characteristics in Esophageal Squamous Cell Carcinoma Patients with TCM Differentiation of Deficiency of Fluid and Blood Based on Non Target Metabolomics [J]. Chinese General Practice, 2025, 28(12): 1513-1519.